Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Eli Lilly's Mounjaro enters Indian market, triggering a sharp rise in consultations as obesity rates climb and patients seek more accessible treatment options ...

Affordability may be a concern in India. It’s only approved for type 2 diabetes and weight loss Price: ₹4,375 ($50.67) for a 5 mg vial, ₹3,500 ($40.54) for a 2.5 mg vial. It is available in ...

Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is ...

For a variety of reasons, Globe Food contributor Kara Baskin took the leap and started Zepbound. But first she worried: "What if I just wasn’t hungry anymore?" Here's how it's going.

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

While the company has not yet launched a product, its VK2735 candidate -- a dual agonist targeting glucagon-like peptide ... 100 million vials and syringe products, and a capacity to produce ...

The reason Lilly is worth so much in the market's eyes is down to one drug molecule, tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon ... single dose vial of ...